
## **Diether Lambrechts**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4037662/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Single-cell Transcriptomics Uncover a Novel Role of Myeloid Cells and T-lymphocytes in the Fibrotic Microenvironment in Peyronie's Disease. European Urology Focus, 2022, 8, 814-828.	1.6	8
2	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 855-871.	1.4	8
3	European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. Annals of Oncology, 2022, 33, 276-287.	0.6	68
4	Antizyme Inhibitor 1 Regulates Matrikine Expression and Enhances the Metastatic Potential of Aggressive Primary Prostate Cancer. Molecular Cancer Research, 2022, 20, 527-541.	1.5	3
5	Rare germline copy number variants (CNVs) and breast cancer risk. Communications Biology, 2022, 5, 65.	2.0	6
6	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	1.4	23
7	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research, 2022, 24, 2.	2.2	15
8	c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial. BMC Medicine, 2022, 20, 59.	2.3	3
9	Abstract P2-08-23: Early intratumoral changes after a single dose of anti-PD-1 treatment in patients with early breast cancer (BC). Cancer Research, 2022, 82, P2-08-23-P2-08-23.	0.4	0
10	Organoids from human tooth showing epithelial stemness phenotype and differentiation potential. Cellular and Molecular Life Sciences, 2022, 79, 153.	2.4	12
11	Role for Granulocyte <scp>Colonyâ€Stimulating</scp> Factor in Neutrophilic Extramedullary Myelopoiesis in a Murine Model of Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2022, 74, 1257-1270.	2.9	6
12	Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer. Gynecologic Oncology, 2022, 165, 14-22.	0.6	14
13	CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer—A Multicenter Analysis. Cancers, 2022, 14, 1954.	1.7	3
14	Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer. Npj Genomic Medicine, 2022, 7, 30.	1.7	4
15	Molecular Heterogeneity Between Paired Primary and Metastatic Lesions from Clear Cell Renal Cell Carcinoma. European Urology Open Science, 2022, 40, 54-57.	0.2	2
16	PHGDH heterogeneity potentiates cancerÂcell dissemination and metastasis. Nature, 2022, 605, 747-753.	13.7	77
17	Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 "CREATE―Trial. International Journal of Molecular Sciences, 2022, 23, 5689.	1.8	2
18	Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion. Facts, Views & Vision in ObGyn, 2022, 14, 111-120.	0.5	1

#	Article	IF	CITATIONS
19	Pan-Cancer Detection and Typing by Mining Patterns in Large Genome-Wide Cell-Free DNA Sequencing Datasets. Clinical Chemistry, 2022, 68, 1164-1176.	1.5	6
20	Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer. Clinical Cancer Research, 2022, 28, 3342-3355.	3.2	3
21	Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis. Npj Breast Cancer, 2022, 8, .	2.3	8
22	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	1.1	12
23	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. Journal of the National Cancer Institute, 2021, 113, 329-337.	3.0	45
24	Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. International Journal of Cancer, 2021, 148, 307-319.	2.3	35
25	Regeneration Defects in Yap and Taz Mutant Mouse Livers Are Caused by Bile Duct Disruption and Cholestasis. Gastroenterology, 2021, 160, 847-862.	0.6	38
26	BCL(X)L and BCL2 increase the metabolic fitness of breast cancer cells: a single-cell imaging study. Cell Death and Differentiation, 2021, 28, 1512-1531.	5.0	15
27	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. British Journal of Cancer, 2021, 124, 842-854.	2.9	5
28	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nature Genetics, 2021, 53, 86-99.	9.4	118
29	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	5.8	19
30	MicroRNAs Possibly Involved in the Development of Bone Metastasis in Clear-Cell Renal Cell Carcinoma. Cancers, 2021, 13, 1554.	1.7	9
31	Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nature Neuroscience, 2021, 24, 595-610.	7.1	288
32	Fat Induces Glucose Metabolism in Nontransformed Liver Cells and Promotes Liver Tumorigenesis. Cancer Research, 2021, 81, 1988-2001.	0.4	43
33	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. European Journal of Cancer, 2021, 146, 30-47.	1.3	81
34	Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2. Nature Genetics, 2021, 53, 435-444.	9.4	162
35	Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?. Cancers, 2021, 13, 2040.	1.7	4
36	Molecular Biomarkers of Response to Eribulin in Patients with Leiomyosarcoma. Clinical Cancer Research, 2021, 27, 3106-3115.	3.2	5

3

#	Article	IF	CITATIONS
37	Prdm16 Supports Arterial Flow Recovery by Maintaining Endothelial Function. Circulation Research, 2021, 129, 63-77.	2.0	15
38	Associations between Genetically Predicted Circulating Protein Concentrations and Endometrial Cancer Risk. Cancers, 2021, 13, 2088.	1.7	10
39	A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nature Medicine, 2021, 27, 820-832.	15.2	330
40	Gene-Environment Interactions Relevant to Estrogen and Risk of Breast Cancer: Can Gene-Environment Interactions Be Detected Only among Candidate SNPs from Genome-Wide Association Studies?. Cancers, 2021, 13, 2370.	1.7	4
41	Current Methodological Challenges of Single-Cell and Single-Nucleus RNA-Sequencing in Glomerular Diseases. Journal of the American Society of Nephrology: JASN, 2021, 32, 1838-1852.	3.0	21
42	Identification of a Locus Near <i>ULK1</i> Associated With Progression-Free Survival in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1669-1680.	1.1	5
43	Interleukin-6 is an activator of pituitary stem cells upon local damage, a competence quenched in the aging gland. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	25
44	Molecular Subtypes and Gene Expression Signatures as Prognostic Features in Fully Resected Clear Cell Renal Cell Carcinoma: A Tailored Approach to Adjuvant Trials. Clinical Genitourinary Cancer, 2021, 19, e382-e394.	0.9	9
45	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. American Journal of Human Genetics, 2021, 108, 1190-1203.	2.6	6
46	Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity. Nature Communications, 2021, 12, 4117.	5.8	170
47	High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification. Genome Medicine, 2021, 13, 111.	3.6	70
48	Genetic analyses of gynecological disease identify genetic relationships between uterine fibroids and endometrial cancer, and a novel endometrial cancer genetic risk region at the WNT4 1p36.12 locus. Human Genetics, 2021, 140, 1353-1365.	1.8	18
49	Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications. Acta Oncológica, 2021, 60, 1499-1506.	0.8	12
50	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Research, 2021, 23, 86.	2.2	7
51	BCL9 regulates CD226 and CD96 checkpoints in CD8+ T cells to improve PD-1 response in cancer. Signal Transduction and Targeted Therapy, 2021, 6, 313.	7.1	16
52	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. British Journal of Cancer, 2021, 125, 1135-1145.	2.9	9
53	Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma. Cancer Cell, 2021, 39, 1135-1149.e8.	7.7	83
54	Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer. Clinical Cancer Research, 2021, 27, 5979-5992.	3.2	5

#	Article	IF	CITATIONS
55	Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome. European Journal of Cancer, 2021, 155, 13-24.	1.3	7
56	Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib. Clinical Cancer Research, 2021, 27, 6737-6748.	3.2	12
57	689P Human leukocyte antigen (HLA) class I/II expression as a predictive biomarker for response to immune oncology (IO) therapy in metastatic clear-cell renal cell carcinoma (m-ccRCC). Annals of Oncology, 2021, 32, S706.	0.6	1
58	Data describing the poor outcome associated with a breast cancer diagnosis in the post-weaning period. Data in Brief, 2021, 38, 107354.	0.5	2
59	Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 623-642.	1.1	19
60	Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages. Cell Research, 2021, 31, 272-290.	5.7	229
61	IL1β Promotes Immune Suppression in the Tumor Microenvironment Independent of the Inflammasome and Gasdermin D. Cancer Immunology Research, 2021, 9, 309-323.	1.6	48
62	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. Scientific Reports, 2021, 11, 19787.	1.6	2
63	Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression. Molecular Cancer, 2021, 20, 136.	7.9	17
64	Multi-tissue transcriptome-wide association study identifies eight candidate genes and tissue-specific gene expression underlying endometrial cancer susceptibility. Communications Biology, 2021, 4, 1211.	2.0	11
65	Clinical practices underlie COVID-19 patient respiratory microbiome composition and its interactions with the host. Nature Communications, 2021, 12, 6243.	5.8	42
66	POLRMT as a Novel Susceptibility Gene for Cardiotoxicity in Epirubicin Treatment of Breast Cancer Patients. Pharmaceutics, 2021, 13, 1942.	2.0	7
67	Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 "CREATE―Trial. Cancers, 2021, 13, 6057.	1.7	9
68	A variant in <i>FTO</i> gene shows association with histological ulceration in cutaneous melanoma. Journal of Cutaneous Pathology, 2020, 47, 98-101.	0.7	4
69	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	9.4	120
70	The genomic landscape of nonsmall cell lung carcinoma in never smokers. International Journal of Cancer, 2020, 146, 3207-3218.	2.3	28
71	Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-sensitive recurrent ovarian cancer. Gynecologic Oncology, 2020, 159, 17-18.	0.6	3
72	Targeting the RhoGEF βPIX/COOL-1 in Glioblastoma: Proof of Concept Studies. Cancers, 2020, 12, 3531.	1.7	4

#	Article	IF	CITATIONS
73	Increased ILâ€10â€producing regulatory T cells are characteristic of severe cases of COVIDâ€19. Clinical and Translational Immunology, 2020, 9, e1204.	1.7	59
74	Establishing a Unified COVID-19 "Immunome― Integrating Coronavirus Pathogenesis and Host Immunopathology. Frontiers in Immunology, 2020, 11, 1642.	2.2	11
75	DNA methylation repels binding of hypoxia-inducible transcription factors to maintain tumor immunotolerance. Genome Biology, 2020, 21, 182.	3.8	39
76	Single-cell transcriptome analysis of the Akimba mouse retina reveals cell-type-specific insights into the pathobiology of diabetic retinopathy. Diabetologia, 2020, 63, 2235-2248.	2.9	43
77	Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome. EBioMedicine, 2020, 56, 102793.	2.7	22
78	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics, 2020, 107, 837-848.	2.6	39
79	Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer. Clinical Cancer Research, 2020, 26, 6254-6265.	3.2	22
80	LBA78 A microsimulation model to assess the impact of SARS-CoV-2 on cancer outcomes, healthcare organization and economic burden. Annals of Oncology, 2020, 31, S1207.	0.6	4
81	LBA81 Keeping exhausted T-cells in check in COVID-19. Annals of Oncology, 2020, 31, S1208.	0.6	0
82	7000 Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N). Annals of Oncology, 2020, 31, S553.	0.6	7
83	817P Response to olaparib monotherapy in relapsed ovarian cancer by HRR gene mutational status and HRD scarring analysis: Results from the randomized phase II CLIO trial. Annals of Oncology, 2020, 31, S617-S618.	0.6	1
84	Validation of the Correlation Between Single Nucleotide Polymorphism rs307826 in VEGFR3 and Outcome in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Sunitinib. Kidney Cancer, 2020, 4, 139-149.	0.2	0
85	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	9.4	265
86	Exposure–response analysis of endoxifen serum concentrations in early-breast cancer. Cancer Chemotherapy and Pharmacology, 2020, 85, 1141-1152.	1.1	10
87	A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling. Cell Research, 2020, 30, 745-762.	5.7	391
88	Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer. Scientific Reports, 2020, 10, 9778.	1.6	5
89	Gemcitabine Recruits M2-Type Tumor-Associated Macrophages into the Stroma of Pancreatic Cancer. Translational Oncology, 2020, 13, 100743.	1.7	34
90	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecologic Oncology, 2020, 158, 702-709.	0.6	15

#	Article	IF	CITATIONS
91	Lipid availability determines fate of skeletal progenitor cells via SOX9. Nature, 2020, 579, 111-117.	13.7	140
92	DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer. Clinical Epigenetics, 2020, 12, 27.	1.8	64
93	Induction and recovery of CpG site specific methylation changes in human bronchial cells after long-term exposure to carbon nanotubes and asbestos. Environment International, 2020, 137, 105530.	4.8	30
94	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	0.6	32
95	An Integrated Gene Expression Landscape Profiling Approach to Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates. Cancer Cell, 2020, 37, 21-36.e13.	7.7	253
96	Precision Therapy in RAS Mutant Colorectal Cancer. Gastroenterology, 2020, 158, 806-811.	0.6	29
97	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. Nature Communications, 2020, 11, 312.	5.8	30
98	Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts. Breast Cancer Research and Treatment, 2020, 181, 423-434.	1.1	14
99	Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models. Stem Cell Reports, 2020, 14, 717-729.	2.3	105
100	Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer. Nature Genetics, 2020, 52, 594-603.	9.4	380
101	A new protocol for single-cell RNA-seq reveals stochastic gene expression during lag phase in budding yeast. ELife, 2020, 9, .	2.8	43
102	Abstract 1118: Absence of mouse-specific tumor evolution in patient-derived cancer xenografts. , 2020, ,		0
103	Abstract 3402: BCAT1 as a druggable target in immuno-oncology. , 2020, , .		0
104	Abstract 4280: Potential molecular biomarkers of response to eribulin in patients with leiomyosarcoma. , 2020, , .		0
105	Abstract 794: Molecular analysis of archival inflammatory myofibroblastic tumor tissue samples from EORTC 90101 "CREATE―and correlation with response to crizotinib. , 2020, , .		0
106	Abstract PD8-02: Phylogenetic reconstruction of advanced breast cancer reveals two different routes of metastatic dissemination associated with distinct clinical outcome. , 2020, , .		0
107	Plasma markers showing differential baseline expression in relapsing versus non-relapsing patients with hormone sensitive breast tumors. European Journal of Cancer, 2020, 138, S73.	1.3	0
108	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Research, 2019, 79, 505-517.	0.4	49

#	Article	IF	CITATIONS
109	ABCG2 Polymorphism rs2231142 and hypothyroidism in metastatic renal cell carcinoma patients treated with sunitinib. Acta Clinica Belgica, 2019, 74, 180-188.	0.5	4
110	Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening. Nature Cell Biology, 2019, 21, 1041-1051.	4.6	281
111	CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition. Oncogene, 2019, 38, 5933-5941.	2.6	16
112	Age-related changes in DNA methylation affect renal histology and post-transplant fibrosis. Kidney International, 2019, 96, 1195-1204.	2.6	17
113	Advanced clear-cell renal cell carcinoma (accRCC): Association of microRNAs (miRNAs) with molecular subtypes, mRNA targets and outcome. Annals of Oncology, 2019, 30, v394-v395.	0.6	0
114	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	2.3	28
115	Pentraxin-3 Polymorphisms are Associated with Invasive Pulmonary Aspergillosis after Lung Transplantation. Journal of Heart and Lung Transplantation, 2019, 38, S117-S118.	0.3	Ο
116	Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524.	1.6	5
117	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	5.8	88
118	Immune cell dynamics induced by a single dose of pembrolizumab as revealed by single-cell RNA profiling. Annals of Oncology, 2019, 30, iii45.	0.6	1
119	Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer. Cancer Letters, 2019, 459, 1-12.	3.2	16
120	Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer. Neoplasia, 2019, 21, 582-590.	2.3	24
121	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. Circulation Genomic and Precision Medicine, 2019, 12, e002470.	1.6	17
122	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. Circulation Genomic and Precision Medicine, 2019, 12, e002471.	1.6	22
123	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. Cancer Medicine, 2019, 8, 2503-2513.	1.3	6
124	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	5.8	90
125	Genomic, Transcriptomic, Epigenetic, and Immune Profiling of Mucinous Breast Cancer. Journal of the National Cancer Institute, 2019, 111, 742-746.	3.0	40
126	Expression of immuneâ€related genes in rectum and colon <i>descendens</i> of Irritable Bowel Syndrome patients is unrelated to clinical symptoms. Neurogastroenterology and Motility, 2019, 31, e13579.	1.6	16

#	Article	IF	CITATIONS
127	Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing. Molecular Cancer Therapeutics, 2019, 18, 1168-1178.	1.9	23
128	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	2.9	52
129	Genetic biomarkers in the VEGF pathway predicting response to anti-VEGF therapy in age-related macular degeneration. BMJ Open Ophthalmology, 2019, 4, e000273.	0.8	10
130	Melanoma susceptibility variant rs869330 in the MTAP gene is associated with melanoma outcome. Melanoma Research, 2019, 29, 590-595.	0.6	2
131	Prediction and clinical utility of a contralateral breast cancer risk model. Breast Cancer Research, 2019, 21, 144.	2.2	24
132	Tumour mutational burden ring trial: Evaluation of targeted next-generation sequencing platforms for implementation in clinical practice. Annals of Oncology, 2019, 30, xi10.	0.6	0
133	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	2.6	711
134	Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib. Clinical Genitourinary Cancer, 2019, 17, e235-e246.	0.9	4
135	Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations. Breast Cancer Research and Treatment, 2019, 174, 55-63.	1.1	3
136	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. International Journal of Epidemiology, 2019, 48, 795-806.	0.9	81
137	Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer Journal of Clinical Oncology, 2019, 37, 5507-5507.	0.8	36
138	Solar Lentigines are Associated with Better Outcome in Cutaneous Melanoma. Acta Dermato-Venereologica, 2019, 99, 1154-1159.	0.6	0
139	Abstract CS1-06: Unraveling lobular breast cancer progression and endocrine resistance mechanisms through genomic and immune characterization of matched primary and metastatic samples. , 2019, , .		0
140	Abstract P4-06-14: Single-cell RNA sequencing to delineate changes in tumor microenvironment induced by immunotherapy. , 2019, , .		0
141	Abstract P3-07-04: Molecular characterization of mucinous breast cancers. , 2019, , .		1
142	EP1126â€Single-cell RNA-sequencing of 7 HGSOC cases reveals multiple prognostic cell subtype. , 2019, , .		0
143	TP53 mutations in cell-free DNA as early markers of therapeutic response in platinum-resistant relapsed ovarian cancer (PROC): a prospective translational analysis of the phase II GANNET53 clinical trial. , 2019, , .		0
144	P115â€Quality-of-life analysis in the randomized phase II CLIO trial comparing olaparib with standard chemotherapy in platinum-resistant recurrent ovarian cancer. , 2019, , .		0

#	Article	IF	CITATIONS
145	The <i>BRCA2</i> c.68-7TÂ>ÂA variant is not pathogenic: A model for clinical calibration of spliceogenicity. Human Mutation, 2018, 39, 729-741.	1.1	19
146	Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial. Clinical Cancer Research, 2018, 24, 2312-2318.	3.2	51
147	Polymorphisms in the Von Hippel–Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors. Clinical Genitourinary Cancer, 2018, 16, 266-273.	0.9	11
148	Ischemia-Induced DNA Hypermethylation during Kidney Transplant Predicts Chronic Allograft Injury. Journal of the American Society of Nephrology: JASN, 2018, 29, 1566-1576.	3.0	27
149	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 2018, 118, 1123-1129.	2.9	15
150	Genetic overlap between endometriosis and endometrial cancer: evidence from crossâ€disease genetic correlation and GWAS metaâ€analyses. Cancer Medicine, 2018, 7, 1978-1987.	1.3	62
151	Somatic <i>POLE</i> exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. Journal of Pathology, 2018, 245, 283-296.	2.1	71
152	Global and gene-specific DNA methylation effects of different asbestos fibres on human bronchial epithelial cells. Environment International, 2018, 115, 301-311.	4.8	10
153	Glucocorticoid receptor DNA methylation and childhood trauma in chronic fatigue syndrome patients. Journal of Psychosomatic Research, 2018, 104, 55-60.	1.2	22
154	Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium. International Journal of Epidemiology, 2018, 47, 526-536.	0.9	88
155	Differences in MWCNT- and SWCNT-induced DNA methylation alterations in association with the nuclear deposition. Particle and Fibre Toxicology, 2018, 15, 11.	2.8	57
156	GLI2 promoter hypermethylation in saliva of children with a respiratory allergy. Clinical Epigenetics, 2018, 10, 50.	1.8	19
157	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2018, 47, 450-459.	0.9	15
158	Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways. International Journal of Cancer, 2018, 142, 1230-1243.	2.3	59
159	Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab. Journal of Clinical Oncology, 2018, 36, 2052-2060.	0.8	26
160	Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. Nature Communications, 2018, 9, 4112.	5.8	55
161	The genetic landscape of 5T models for multiple myeloma. Scientific Reports, 2018, 8, 15030.	1.6	15
162	The genetic landscape of 87 ovarian germ cell tumors. Gynecologic Oncology, 2018, 151, 61-68.	0.6	44

#	Article	IF	CITATIONS
163	Self-Maintaining Gut Macrophages Are Essential for Intestinal Homeostasis. Cell, 2018, 175, 400-415.e13.	13.5	371
164	Cigarette Smoke–Induced Emphysema Exhausts Early Cytotoxic CD8+ T Cell Responses against Nascent Lung Cancer Cells. Journal of Immunology, 2018, 201, 1558-1569.	0.4	19
165	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 2018, 13, e0197561.	1.1	9
166	Phenotype molding of stromal cells in the lung tumor microenvironment. Nature Medicine, 2018, 24, 1277-1289.	15.2	1,126
167	RNA-sequencing in non-small cell lung cancer shows gene downregulation of therapeutic targets in tumor tissue compared to non-malignant lung tissue. Radiation Oncology, 2018, 13, 131.	1.2	8
168	Identification of nine new susceptibility loci for endometrial cancer. Nature Communications, 2018, 9, 3166.	5.8	178
169	Quiescent Endothelial Cells Upregulate Fatty Acid β-Oxidation for Vasculoprotection via Redox Homeostasis. Cell Metabolism, 2018, 28, 881-894.e13.	7.2	174
170	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	1.8	3
171	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018, 50, 968-978.	9.4	184
172	Detection of microsatellite instability (MSI) in colorectal cancer samples with a novel set of highly sensitive markers by means of the Idylla MSI Test prototype Journal of Clinical Oncology, 2018, 36, e15639-e15639.	0.8	12
173	Association of a novel set of 7 homopolymer indels for detection of MSI with tumor mutation burden and total indel load in endometrial and colorectal cancers Journal of Clinical Oncology, 2018, 36, e15654-e15654.	0.8	2
174	A machine-learning approach for the identification of highly predictive germline SNPs as biomarkers for response to bevacizumab in metastatic colorectal cancer using Elastic Net and Lasso Journal of Clinical Oncology, 2018, 36, e15584-e15584.	0.8	1
175	Abstract 2579: Loss of chromosome 18q11.2-18q12.1 is predictive for progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. , 2018, , .		0
176	Abstract 230: Joint genome-wide association study of endometrial cancer and ovarian cancer identifies a novel genetic risk region at 14q23.3. , 2018, , .		0
177	Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype. Pharmacogenomics Journal, 2017, 17, 556-562.	0.9	16
178	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 2017, 116, 524-535.	2.9	23
179	Centrosome Amplification Is Sufficient to Promote Spontaneous Tumorigenesis in Mammals. Developmental Cell, 2017, 40, 313-322.e5.	3.1	291
180	<i>BRCA2</i> Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. Cancer Research, 2017, 77, 2789-2799.	0.4	75

#	Article	IF	CITATIONS
181	Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations. Nature Communications, 2017, 8, 14944.	5.8	126
182	It's T Time for Normal Blood Vessels. Developmental Cell, 2017, 41, 125-126.	3.1	6
183	Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. Nature Genetics, 2017, 49, 834-841.	9.4	426
184	Lineage-specific functions of TET1 in the postimplantation mouse embryo. Nature Genetics, 2017, 49, 1061-1072.	9.4	96
185	Do COPD subtypes really exist? COPD heterogeneity and clustering in 10 independent cohorts. Thorax, 2017, 72, 998-1006.	2.7	65
186	Establishment and characterization of uterine sarcoma and carcinosarcoma patient-derived xenograft models. Gynecologic Oncology, 2017, 146, 538-545.	0.6	16
187	CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. Nature, 2017, 546, 168-172.	13.7	222
188	Limited potential of genetic predisposition scores to predict muscle mass and strength performance in Flemish Caucasians between 19 and 73 years of age. Physiological Genomics, 2017, 49, 160-166.	1.0	10
189	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
190	Epigenetic effects of carbon nanotubes in human monocytic cells. Mutagenesis, 2017, 32, 181-191.	1.0	46
191	The role of fatty acid $\hat{I}^2$ -oxidation in lymphangiogenesis. Nature, 2017, 542, 49-54.	13.7	240
192	Acriflavine Inhibits Acquired Drug Resistance by Blocking the Epithelial-to-Mesenchymal Transition and the Unfolded Protein Response. Translational Oncology, 2017, 10, 59-69.	1.7	37
193	Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. Cancer Causes and Control, 2017, 28, 459-468.	0.8	20
194	A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2017, 23, 7621-7632.	3.2	31
195	Impact of Selection Bias on Estimation of Subsequent Event Risk. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	28
196	Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma. Clinical Cancer Research, 2017, 23, 7232-7241.	3.2	37
197	Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer. European Journal of Cancer, 2017, 86, 5-14.	1.3	49
198	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	13.7	1,099

#	Article	IF	CITATIONS
199	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
200	Gene–environment interactions involving functional variants: Results from the Breast Cancer Association Consortium. International Journal of Cancer, 2017, 141, 1830-1840.	2.3	20
201	Geneâ€based interaction analysis shows <scp>GABA</scp> ergic genes interacting with parenting in adolescent depressive symptoms. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2017, 58, 1301-1309.	3.1	16
202	Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses. Clinical Cancer Research, 2017, 23, 2223-2231.	3.2	80
203	Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. Genetics in Medicine, 2017, 19, 599-603.	1.1	67
204	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 420-424.	1.1	3
205	Neurogenic Radial Glia-like Cells in Meninges Migrate and Differentiate into Functionally Integrated Neurons in the Neonatal Cortex. Cell Stem Cell, 2017, 20, 360-373.e7.	5.2	64
206	Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching. British Journal of Cancer, 2017, 116, 58-65.	2.9	124
207	Body mass index and breast cancer survival: a Mendelian randomization analysis. International Journal of Epidemiology, 2017, 46, 1814-1822.	0.9	45
208	Postmortem Examination of an Aggressive Case of Medullary Thyroid Carcinoma Characterized by Catastrophic Genomic Abnormalities. JCO Precision Oncology, 2017, 1, 1-7.	1.5	1
209	Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial. BMC Cancer, 2017, 17, 562.	1.1	31
210	The footprint of the ageing stroma in older patients with breast cancer. Breast Cancer Research, 2017, 19, 78.	2.2	22
211	Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. Breast Cancer Research, 2017, 19, 119.	2.2	43
212	Newborn genome-wide DNA methylation in association with pregnancy anxiety reveals a potential role for GABBR1. Clinical Epigenetics, 2017, 9, 107.	1.8	34
213	New cell line models for the development of personalized therapy for high grade serous ovarian cancer. Annals of Oncology, 2017, 28, vii15-vii16.	0.6	0
214	Implementing liquid biopsies into clinical decision making for cancer immunotherapy. Oncotarget, 2017, 8, 48507-48520.	0.8	63
215	Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma. Journal of Clinical Investigation, 2017, 127, 2310-2325.	3.9	26
216	Identification of a novel predictive genomic biomarker for response to combination bevacizumab in metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2017, 35, 3580-3580.	0.8	2

#	Article	IF	CITATIONS
217	TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. Oncotarget, 2017, 8, 18381-18398.	0.8	14
218	Assessment of concordance between fresh-frozen and formalin-fixed paraffin embedded tumor DNA methylation using a targeted sequencing approach. Oncotarget, 2017, 8, 48126-48137.	0.8	12
219	Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. Oncotarget, 2017, 8, 64670-64684.	0.8	7
220	<i>PHIP</i> - a novel candidate breast cancer susceptibility locus on 6q14.1. Oncotarget, 2017, 8, 102769-102782.	0.8	9
221	Abstract P2-03-05: Identification, clinical characteristics and treatment outcomes of somatic human epidermal growth factor receptor 2 (ERBB2) mutations in metastatic breast cancer patients. , 2017, , .		0
222	Abstract P1-01-10: Exome sequencing of circulating tumor cells in metastatic breast cancer. , 2017, , .		0
223	Abstract P4-03-01: The footprint of the aging stroma in older breast cancer patients. , 2017, , .		0
224	Abstract 3397: Post-mortem examination of an aggressive case of medullary thyroid cancer characterised by catastrophic genomic abnormalities. , 2017, , .		0
225	Genetic variation in the STAT3 gene has an impact on survival after lung transplantation. , 2017, , .		0
226	Polymorphisms in immunosuppression transporters affect outcome after lung transplantation. , 2017, , .		0
227	Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. Oncotarget, 2016, 7, 80140-80163.	0.8	31
228	Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1. Oncotarget, 2016, 7, 24326-24338.	0.8	33
229	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 884-895.	0.9	71
230	Fineâ€scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. International Journal of Cancer, 2016, 139, 1303-1317.	2.3	51
231	p53 induces formation of NEAT1 lncRNA-containing paraspeckles that modulate replication stress response and chemosensitivity. Nature Medicine, 2016, 22, 861-868.	15.2	372
232	Relief of hypoxia by angiogenesis promotes neural stem cell differentiation by targeting glycolysis. EMBO Journal, 2016, 35, 924-941.	3.5	161
233	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	1.5	174
234	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	2.2	31

#	Article	IF	CITATIONS
235	Chromosome 18q11.2 loss as a predictive marker for response to bevacizumab in metastatic colorectal cancer. European Journal of Cancer, 2016, 69, S29.	1.3	4
236	International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Non–Small Cell Lung Cancer: Realities and Hopes. Journal of Thoracic Oncology, 2016, 11, 1153-1169.	0.5	9
237	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics, 2016, 135, 741-756.	1.8	19
238	Genetic predisposition to ductal carcinoma in situ of the breast. Breast Cancer Research, 2016, 18, 22.	2.2	43
239	Five endometrial cancer risk loci identified through genome-wide association analysis. Nature Genetics, 2016, 48, 667-674.	9.4	77
240	The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. Cancer Research, 2016, 76, 2778-2790.	0.4	208
241	Improved metabolite identification with MIDAS and MAGMa through MS/MS spectral dataset-driven parameter optimization. Metabolomics, 2016, 12, 1.	1.4	35
242	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 1619-1630.	0.9	111
243	OC-0047: PD-L1/PD-L2 gene expression differs in tumor vs. lung tissue in non-small cell lung cancer patients. Radiotherapy and Oncology, 2016, 119, S19-S20.	0.3	0
244	Expression profiling of tumour budding cells in colorectal cancer suggests an EMT-like phenotype and molecular subtype switching. European Journal of Cancer, 2016, 61, S88.	1.3	3
245	TET enzymes as oxygen-dependent tumor suppressors: exciting new avenues for cancer management. Epigenomics, 2016, 8, 1445-1448.	1.0	9
246	An oncogenomics-based in vivo screen identifies novel melanoma tumor-suppressors. European Journal of Cancer, 2016, 61, S30-S31.	1.3	0
247	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. American Journal of Human Genetics, 2016, 99, 903-911.	2.6	59
248	An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. Human Molecular Genetics, 2016, 25, 3863-3876.	1.4	33
249	Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1503-1510.	1.1	64
250	Tumour hypoxia causes DNA hypermethylation by reducing TET activity. Nature, 2016, 537, 63-68.	13.7	521
251	Successful application of endoscopic ultrasound-guided fine needle biopsy to establish pancreatic patient-derived tumor xenografts: a pilot study. Endoscopy, 2016, 48, 1016-1022.	1.0	10
252	Allele-specific DNA methylation reinforces PEAR1 enhancer activity. Blood, 2016, 128, 1003-1012.	0.6	48

#	Article	IF	CITATIONS
253	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	7.7	157
254	Validation of <scp>VEGFR</scp> 1 rs9582036 as predictive biomarker in metastatic clearâ€eell renal cell carcinoma patients treated with sunitinib. BJU International, 2016, 118, 890-901.	1.3	23
255	Tumors smother their epigenome. Molecular and Cellular Oncology, 2016, 3, e1240549.	0.3	8
256	Inhibition of the Glycolytic Activator PFKFB3 in Endothelium Induces Tumor Vessel Normalization, Impairs Metastasis, and Improves Chemotherapy. Cancer Cell, 2016, 30, 968-985.	7.7	464
257	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	5.8	93
258	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	5.8	78
259	Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative. Digestion, 2016, 94, 129-137.	1.2	10
260	Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). Scientific Reports, 2016, 6, 32512.	1.6	19
261	The Emerging Role of DNA Methylation in Kidney Transplantation: A Perspective. American Journal of Transplantation, 2016, 16, 1070-1078.	2.6	22
262	Vascular endothelial growth factor pathway in endometriosis: genetic variants and plasma biomarkers. Fertility and Sterility, 2016, 105, 988-996.	0.5	36
263	CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer. Endocrine-Related Cancer, 2016, 23, 77-91.	1.6	62
264	Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer. European Journal of Cancer, 2016, 53, 51-64.	1.3	45
265	Genetic predisposition for beta cell fragility underlies type 1 and type 2 diabetes. Nature Genetics, 2016, 48, 519-527.	9.4	117
266	HIF-1α Promotes Glutamine-Mediated Redox Homeostasis and Glycogen-Dependent Bioenergetics to Support Postimplantation Bone Cell Survival. Cell Metabolism, 2016, 23, 265-279.	7.2	142
267	Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients. European Journal of Cancer, 2016, 56, 31-36.	1.3	23
268	No evidence that protein truncating variants in <i>BRIP1</i> are associated with breast cancer risk: implications for gene panel testing. Journal of Medical Genetics, 2016, 53, 298-309.	1.5	94
269	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	9.4	125
270	Genomic Characterization of Primary Invasive Lobular Breast Cancer. Journal of Clinical Oncology, 2016, 34, 1872-1881.	0.8	249

#	Article	IF	CITATIONS
271	Transient PLK4 overexpression accelerates tumorigenesis in p53-deficient epidermis. Nature Cell Biology, 2016, 18, 100-110.	4.6	145
272	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute, 2016, 108, djv315.	3.0	77
273	Evidence of a genetic link between endometriosis and ovarian cancer. Fertility and Sterility, 2016, 105, 35-43.e10.	0.5	37
274	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	0.6	18
275	Prospective study evaluating the effect of impaired tamoxifen metabolisation on efficacy in breast cancer patients receiving tamoxifen in the neo-adjuvant or metastatic setting Journal of Clinical Oncology, 2016, 34, 523-523.	0.8	4
276	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	0.8	5
277	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. Oncotarget, 2016, 7, 72381-72394.	0.8	13
278	Germline polymorphisms in an enhancer of <i>PSIP1</i> are associated with progression-free survival in epithelial ovarian cancer. Oncotarget, 2016, 7, 6353-6368.	0.8	29
279	Genomic Characterisation and Response to Trastuzumab and Paclitaxel in Advanced or Recurrent HER2-positive Endometrial Carcinoma. Anticancer Research, 2016, 36, 5381-5384.	0.5	6
280	Abstract P3-07-46: CYPTAM-BRUT 3: Endometrial thickness cannot be used as a marker for tamoxifen metabolization in postmenopausal breast cancer patients. Cancer Research, 2016, 76, P3-07-46-P3-07-46.	0.4	2
281	Abstract P4-10-07: Genetic predictors of chemotherapy-related amenorrhea. , 2016, , .		0
282	Abstract 5197: Patient-derived xenograft (PDX) models of soft tissue sarcoma (STS): a preclinical platform for early drug testing. , 2016, , .		0
283	Abstract 4529: Tailoring approaches for global epigenome analysis from archival formalin-fixed paraffin-embedded tissue samples. , 2016, , .		0
284	A child's spit epigenome can reveal its respiratory allergy risk. , 2016, , .		0
285	Investigation of geneâ€environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. International Journal of Cancer, 2015, 136, E685-96.	2.3	34
286	Uncovering the genomic heterogeneity of multifocal breast cancer. Journal of Pathology, 2015, 236, 457-466.	2.1	72
287	Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. Scientific Reports, 2015, 5, 17369.	1.6	35
288	(Epi)genetic variation in ageing of metabolic fitness. Archives of Public Health, 2015, 73, .	1.0	0

#	Article	IF	CITATIONS
289	Epithelialâ€Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 2015, 39, 689-697.	0.6	22
290	A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients. BMC Cancer, 2015, 15, 978.	1.1	6
291	Genetic variants in <scp>VEGF</scp> pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III <scp>G</scp> epar <scp>Q</scp> uinto study. International Journal of Cancer, 2015, 137, 2981-2988.	2.3	31
292	DNA methylation in imprinted genes <scp><i>IGF2</i></scp> and <scp><i>GNASXL</i></scp> is associated with prenatal maternal stress. Genes, Brain and Behavior, 2015, 14, 573-582.	1.1	48
293	Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair. Obstetrical and Gynecological Survey, 2015, 70, 758-762.	0.2	0
294	Chronic Fatigue Syndrome and DNA Hypomethylation of the Glucocorticoid Receptor Gene Promoter 1F Region. Psychosomatic Medicine, 2015, 77, 853-862.	1.3	39
295	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	1.1	44
296	Phospholipase C gamma 1 (PLCG1) R707Q mutation is counterselected under targeted therapy in a patient with hepatic angiosarcoma. Oncotarget, 2015, 6, 36418-36425.	0.8	40
297	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. Journal of the National Cancer Institute, 2015, 107, .	3.0	428
298	Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy. Targeted Oncology, 2015, 10, 583-596.	1.7	23
299	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Human Molecular Genetics, 2015, 24, 3595-3607.	1.4	40
300	Genomic hallmarks of invasive lobular breast carcinoma and their clinical relevance. Annals of Oncology, 2015, 26, vi3.	0.6	0
301	Germline Mutation in <i>BRCA1</i> or <i>BRCA2</i> and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer. Clinical Cancer Research, 2015, 21, 652-657.	3.2	138
302	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. Human Molecular Genetics, 2015, 24, 2966-2984.	1.4	40
303	DNA methylation analysis of Homeobox genes implicates <i>HOXB7</i> hypomethylation as risk factor for neural tube defects. Epigenetics, 2015, 10, 92-101.	1.3	33
304	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. American Journal of Human Genetics, 2015, 96, 5-20.	2.6	76
305	Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer. Journal of the National Cancer Institute, 2015, 107, 402.	3.0	229
306	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. Carcinogenesis, 2015, 36, 256-271.	1.3	14

#	Article	IF	CITATIONS
307	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
308	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Genetics, 2015, 47, 373-380.	9.4	513
309	A Genetic Predisposition Score Associates with Reduced Aerobic Capacity in Response to Acute Normobaric Hypoxia in Lowlanders. High Altitude Medicine and Biology, 2015, 16, 34-42.	0.5	6
310	Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature Genetics, 2015, 47, 888-897.	9.4	78
311	Interleukin-17 receptor polymorphism predisposes to primary graft dysfunction after lung transplantation. Journal of Heart and Lung Transplantation, 2015, 34, 941-949.	0.3	27
312	The Cancer Cell Oxygen Sensor PHD2 Promotes Metastasis via Activation of Cancer-Associated Fibroblasts. Cell Reports, 2015, 12, 992-1005.	2.9	66
313	Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer. Cancer Letters, 2015, 362, 218-228.	3.2	22
314	Network-Based Integration of GWAS and Gene Expression Identifies a <i>HOX</i> -Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	1.1	28
315	Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies. Gynecologic Oncology, 2015, 139, 118-126.	0.6	52
316	Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. British Journal of Cancer, 2015, 113, 817-826.	2.9	111
317	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 2015, 21, 5264-5276.	3.2	33
318	Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. Nature Medicine, 2015, 21, 946-954.	15.2	179
319	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. American Journal of Human Genetics, 2015, 97, 22-34.	2.6	37
320	Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models. Gynecologic Oncology, 2015, 138, 165-173.	0.6	26
321	Identification of Novel Genetic Markers of Breast Cancer Survival. Journal of the National Cancer Institute, 2015, 107, .	3.0	56
322	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	0.6	15
323	Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 415-422.	1.4	34
324	Candidate locus analysis of the TERT–CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk. Human Genetics, 2015, 134, 231-245.	1.8	34

#	Article	IF	CITATIONS
325	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. Breast Cancer Research, 2015, 17, 18.	2.2	20
326	Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer. BMC Pharmacology & Toxicology, 2015, 16, 2.	1.0	33
327	The diagnostic value of next generation sequencing in familial nonsyndromic congenital heart defects. American Journal of Medical Genetics, Part A, 2015, 167, 1822-1829.	0.7	48
328	Microsatellite Instable and Microsatellite Stable Primary Endometrial Carcinoma Cells and Their Subcutaneous and Orthotopic Xenografts Recapitulate the Characteristics of the Corresponding Primary Tumor. International Journal of Gynecological Cancer, 2015, 25, 363-371.	1.2	6
329	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	5.8	63
330	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nature Genetics, 2015, 47, 1294-1303.	9.4	357
331	Common variants at the <i>CHEK2</i> gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	1.3	24
332	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics, 2015, 24, 5955-5964.	1.4	68
333	The antitumor effect of metformin with and without carboplatin on primary endometrioid endometrial carcinoma in vivo. Gynecologic Oncology, 2015, 138, 378-382.	0.6	5
334	Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients. Breast Cancer Research and Treatment, 2015, 152, 67-76.	1.1	61
335	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. Journal of the National Cancer Institute, 2015, 107, djv219.	3.0	99
336	DNA methylation profiling of non-small cell lung cancer reveals a COPD-driven immune-related signature. Thorax, 2015, 70, 1113-1122.	2.7	37
337	Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer. Endocrine-Related Cancer, 2015, 22, 851-861.	1.6	25
338	Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting. British Journal of Cancer, 2015, 113, 1027-1034.	2.9	34
339	Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1680-1691.	1.1	24
340	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Human Molecular Genetics, 2015, 24, 285-298.	1.4	38
341	Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. Human Molecular Genetics, 2015, 24, 1478-1492.	1.4	50
342	Abstract S2-05: Characterization and clinical relevance of the genomic alterations defining lobular breast cancer2015		1

breast cancer., 2015,,.

#	Article	IF	CITATIONS
343	The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. Oncotarget, 2015, 6, 7390-7407.	0.8	15
344	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, .	0.3	25
345	Abstract OT2-1-05: Prospective multicenter study evaluating the effect of impaired tamoxifen metabolization on efficacy in breast cancer patients receiving tamoxifen in the neo-adjuvant or metastatic setting - The CYPTAM-BRUT 2 trial. , 2015, , .		0
346	Abstract PD3-7: Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analyses in breast cancer. , 2015, , .		0
347	Abstract P1-03-05: Genetic variant in the OPG gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients. , 2015, , .		0
348	Abstract 2779: A genome-wide analysis of more than 160,000 individuals identifies four novel pleiotropic risk loci shared between breast and ovarian cancer. , 2015, , .		0
349	Abstract CT135: Uncovering the genomic heterogeneity of multifocal breast cancer. , 2015, , .		0
350	Abstract AS13: Epidemiologic predictors of pre-treatment CA125 in women with ovarian cancer. , 2015, , $\cdot$		0
351	MicroRNA Related Polymorphisms and Breast Cancer Risk. PLoS ONE, 2014, 9, e109973.	1.1	49
352	25(OH)D2 Half-Life Is Shorter Than 25(OH)D3 Half-Life and Is Influenced by DBP Concentration and Genotype. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3373-3381.	1.8	203
353	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. PLoS Genetics, 2014, 10, e1004285.	1.5	39
354	Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. Acta Oncológica, 2014, 53, 1413-1422.	0.8	30
355	Genetic variants in <i>CDC42</i> and <i>NXPH1</i> as susceptibility factors for constipation and diarrhoea predominant irritable bowel syndrome. Gut, 2014, 63, 1103-1111.	6.1	49
356	Variation in NF-κB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1421-1427.	1.1	13
357	2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. Nature Communications, 2014, 5, 4051.	5.8	16
358	15 Genetic and molecular validation of uterine sarcoma patient-derived xenograft models. European Journal of Cancer, 2014, 50, 11.	1.3	0
359	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2014, 23, 6096-6111.	1.4	53
360	Genetic variation in the <i>lymphotoxin-α</i> ( <i>LTA</i> )/ <i>tumour necrosis factor-α</i> ( <i>TNFα</i> ) locus as a risk factor for idiopathic achalasia. Gut, 2014, 63, 1401-1409.	6.1	21

#	Article	IF	CITATIONS
361	ABCA Transporter Gene Expression and Poor Outcome in Epithelial Ovarian Cancer. Journal of the National Cancer Institute, 2014, 106, .	3.0	107
362	Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer. Gynecologic Oncology, 2014, 135, 415-422.	0.6	38
363	Genetic Variation in Immunoglobulin G Receptor Affects Survival After Lung Transplantation. American Journal of Transplantation, 2014, 14, 1672-1677.	2.6	4
364	Genome dynamics of the human embryonic kidney 293 lineage in response to cell biology manipulations. Nature Communications, 2014, 5, 4767.	5.8	421
365	FISH analysis of PTEN in endometrial carcinoma. comparison with SNP arrays and MLPA. Histopathology, 2014, 65, 371-388.	1.6	3
366	VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib – a multicentric retrospective analysis. Acta Oncológica, 2014, 53, 103-112.	0.8	45
367	Epithelial Ovarian Cancer: Rationale for Changing the One-Fits-All Standard Treatment Regimen to Subtype-Specific Treatment. International Journal of Gynecological Cancer, 2014, 24, 468-477.	1.2	30
368	Risk of Ovarian Cancer and the NF-κB Pathway: Genetic Association with <i>IL1A</i> and <i>TNFSF10</i> . Cancer Research, 2014, 74, 852-861.	0.4	48
369	Large-Scale Evaluation of Common Variation in Regulatory T Cell–Related Genes and Ovarian Cancer Outcome. Cancer Immunology Research, 2014, 2, 332-340.	1.6	21
370	Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy. Angiogenesis, 2014, 17, 909-920.	3.7	40
371	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium. Human Molecular Genetics, 2014, 23, 1934-1946.	1.4	32
372	Genetic markers of bevacizumab-induced hypertension. Angiogenesis, 2014, 17, 685-94.	3.7	24
373	Cenome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human Genetics, 2014, 133, 481-497.	1.8	23
374	Identification of New Genetic Susceptibility Loci for Breast Cancer Through Consideration of Geneâ€Environment Interactions. Genetic Epidemiology, 2014, 38, 84-93.	0.6	28
375	Association of <i>CDH11</i> with nonâ€syndromic ASD. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 391-398.	1.1	15
376	Exome sequencing reveals HINT1 mutations as a cause of distal hereditary motor neuropathy. European Journal of Human Genetics, 2014, 22, 847-850.	1.4	33
377	Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel. Breast Cancer Research and Treatment, 2014, 147, 557-570.	1.1	23
378	Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Annals of Oncology, 2014, 25, 1959-1965.	0.6	206

#	Article	IF	CITATIONS
379	Consortium analysis of gene and gene–folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition and Food Research, 2014, 58, 2023-2035.	1.5	16
380	FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. British Journal of Cancer, 2014, 110, 1088-1100.	2.9	21
381	Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. Nature, 2014, 514, 92-97.	13.7	548
382	The rs1800716 variant in CYP2D6 is associated with an increased double endometrial thickness in postmenopausal women on tamoxifen. Annals of Oncology, 2014, 25, 90-95.	0.6	11
383	Sequencing an Ashkenazi reference panel supports population-targeted personal genomics and illuminates Jewish and European origins. Nature Communications, 2014, 5, 4835.	5.8	156
384	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nature Communications, 2014, 5, 4999.	5.8	105
385	Biology of breast cancer during pregnancy using genomic profiling. Endocrine-Related Cancer, 2014, 21, 545-554.	1.6	58
386	Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors. BMC Cancer, 2014, 14, 201.	1.1	20
387	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. Human Molecular Genetics, 2014, 23, 6034-6046.	1.4	12
388	Genetic Variation in Immunoglobulin G Receptor Affects Survival After Lung Transplantation. Journal of Heart and Lung Transplantation, 2014, 33, S30.	0.3	0
389	A Genetic Polymorphism in IL-23 Receptor Is Protective for Primary Graft Dysfunction. Journal of Heart and Lung Transplantation, 2014, 33, S138-S139.	0.3	0
390	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast Cancer Research, 2014, 16, R51.	2.2	14
391	CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations. Clinical Pharmacology and Therapeutics, 2014, 95, 216-227.	2.3	150
392	Genetic Variation in Caveolin-1 Affects Survival After Lung Transplantation. Transplantation, 2014, 98, 354-359.	0.5	6
393	Abstract 986: Unraveling breast cancer progression through geographical and temporal sequencing. , 2014, , .		5
394	Mismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks. ELife, 2014, 3, e02725.	2.8	71
395	Mixed adenoneuroendocrine carcinoma of the colon: molecular pathogenesis and treatment. Anticancer Research, 2014, 34, 5517-21.	0.5	46
396	Olmsted syndrome: exploration of the immunological phenotype. Orphanet Journal of Rare Diseases, 2013, 8, 79.	1.2	45

#	Article	IF	CITATIONS
397	Functional Association between a Genetic Variant in the IL-17 Receptor Gene and Chronic Rejection after Lung Transplantation. Journal of Heart and Lung Transplantation, 2013, 32, S33.	0.3	0
398	Genetic variation in interleukin-17 receptor A is functionally associated with chronic rejection after lung transplantation. Journal of Heart and Lung Transplantation, 2013, 32, 1233-1240.	0.3	18
399	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-370.	9.4	326
400	Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). Annals of Oncology, 2013, 24, 1513-1525.	0.6	57
401	Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. American Journal of Human Genetics, 2013, 93, 1046-1060.	2.6	98
402	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
403	Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting. British Journal of Cancer, 2013, 108, 1358-1367.	2.9	148
404	Markers of Response for the Antiangiogenic Agent Bevacizumab. Journal of Clinical Oncology, 2013, 31, 1219-1230.	0.8	309
405	Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers. American Journal of Human Genetics, 2013, 92, 489-503.	2.6	201
406	Survival after Lung Transplantation Is Linked with a Genetic Polymorphism in Caveolin-1. Journal of Heart and Lung Transplantation, 2013, 32, S120-S121.	0.3	0
407	Genome-wide association studies identify four ER negative–specific breast cancer risk loci. Nature Genetics, 2013, 45, 392-398.	9.4	374
408	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics, 2013, 45, 353-361.	9.4	960
409	Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. British Journal of Cancer, 2013, 108, 887-900.	2.9	88
410	Therapeutic potential of VEGF and VEGF-derived peptide in peripheral neuropathies. Neuroscience, 2013, 244, 77-89.	1.1	50
411	Inhibition of Tumor Angiogenesis and Growth by a Small-Molecule Multi-FGF Receptor Blocker with Allosteric Properties. Cancer Cell, 2013, 23, 477-488.	7.7	138
412	High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. Gynecologic Oncology, 2013, 128, 327-334.	0.6	68
413	Influence of 23 coronary artery disease variants on recurrent myocardial infarction or cardiac death: the GRACE Genetics Study. European Heart Journal, 2013, 34, 993-1001.	1.0	35
414	Polymorphisms in Inflammation Pathway Genes and Endometrial Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 216-223.	1.1	22

#	Article	IF	CITATIONS
415	Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. PLoS Genetics, 2013, 9, e1003173.	1.5	105
416	Evidence of Gene–Environment Interactions between Common Breast Cancer Susceptibility Loci and Established Environmental Risk Factors. PLoS Genetics, 2013, 9, e1003284.	1.5	136
417	Why Should Results From Metastatic Trials No Longer Matter for Early-Stage Disease?. Journal of Clinical Oncology, 2013, 31, 2753-2753.	0.8	5
418	Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer. Journal of the National Cancer Institute, 2013, 105, 960-967.	3.0	138
419	Genetic changes in nonepithelial ovarian cancer. Expert Review of Anticancer Therapy, 2013, 13, 871-882.	1.1	16
420	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications, 2013, 4, 1628.	5.8	144
421	Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 987-992.	1.1	20
422	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications, 2013, 4, 1627.	5.8	98
423	Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab. Clinical Cancer Research, 2013, 19, 4104-4113.	3.2	95
424	Genetic Predisposition Scores Associate with Muscular Strength, Size, and Trainability. Medicine and Science in Sports and Exercise, 2013, 45, 1451-1459.	0.2	24
425	Variants in the 15q24/25 Locus Associate with Lung Function Decline in Active Smokers. PLoS ONE, 2013, 8, e53219.	1.1	5
426	Abstract OT3-2-04: Prospective multicenter study evaluating the effect of impaired tamoxifen metabolization on efficacy in breast cancer patients receiving tamoxifen in the neo-adjuvant or metastatic setting - The CYPTAM-BRUT 2 trial. , 2013, , .		0
427	Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency. Carcinogenesis, 2012, 33, 1319-1326.	1.3	95
428	Whole-genome sequencing reveals a coding non-pathogenic variant tagging a non-coding pathogenic hexanucleotide repeat expansion in C9orf72 as cause of amyotrophic lateral sclerosis. Human Molecular Genetics, 2012, 21, 2412-2419.	1.4	33
429	19p13.1 Is a Triple-Negative–Specific Breast Cancer Susceptibility Locus. Cancer Research, 2012, 72, 1795-1803.	0.4	100
430	Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing. Nature Biotechnology, 2012, 30, 61-68.	9.4	211
431	<i>CHEK2</i> *1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancer–Specific Death, and Increased Risk of a Second Breast Cancer. Journal of Clinical Oncology, 2012, 30, 4308-4316.	0.8	162
432	Genome-Wide Association Study for Ovarian Cancer Susceptibility Using Pooled DNA. Twin Research and Human Genetics, 2012, 15, 615-623.	0.3	8

#	Article	IF	CITATIONS
433	The role of genetic breast cancer susceptibility variants as prognostic factors. Human Molecular Genetics, 2012, 21, 3926-3939.	1.4	80
434	Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet, The, 2012, 380, 572-580.	6.3	1,937
435	Association Between <emph type="ital">BRCA1</emph> and <emph type="ital"&gt;BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer. JAMA - Journal of the American Medical Association, 2012, 307, 382.</emph 	3.8	546
436	VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncology, The, 2012, 13, 724-733.	5.1	174
437	796 Establishment of Primary Endometrial Carcinoma Cell Cultures as a Preclinical Tool for Drug Screening – Methods and Characterization. European Journal of Cancer, 2012, 48, S189-S190.	1.3	1
438	Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nature Genetics, 2012, 44, 312-318.	9.4	256
439	Systemic anti-vascular endothelial growth factor therapies induce a painful sensory neuropathy. Brain, 2012, 135, 2629-2641.	3.7	53
440	9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1783-1791.	1.1	17
441	208 IL-23R Locus Polymorphism Is Associated with Higher Mortality, after Lung Transplantation. Journal of Heart and Lung Transplantation, 2012, 31, S78.	0.3	Ο
442	210 Toll-Like Receptor 4 Polymorphisms and the Risk of Primary Graft Dysfunction after Lung Transplantation. Journal of Heart and Lung Transplantation, 2012, 31, S78.	0.3	0
443	Influence of rs5065 Atrial Natriuretic Peptide Gene Variant on Coronary Artery Disease. Journal of the American College of Cardiology, 2012, 59, 1763-1770.	1.2	40
444	Accelerated Lung Function Decline in Smokers. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 579-581.	2.5	0
445	Huvariome: a web server resource of whole genome next-generation sequencing allelic frequencies to aid in pathological candidate gene selection. Journal of Clinical Bioinformatics, 2012, 2, 19.	1.2	20
446	Methylation Defect in Imprinted Genes Detected in Patients with an Albright's Hereditary Osteodystrophy Like Phenotype and Platelet Gs Hypofunction. PLoS ONE, 2012, 7, e38579.	1.1	21
447	VEGF Receptor-2 (Flk-1) Overexpression in Mice Counteracts Focal Epileptic Seizures. PLoS ONE, 2012, 7, e40535.	1.1	20
448	Comprehensive Mutation Analysis in Colorectal Flat Adenomas. PLoS ONE, 2012, 7, e41963.	1.1	20
449	Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. PLoS ONE, 2012, 7, e35706.	1.1	11
450	11q13 is a susceptibility locus for hormone receptor positive breast cancer. Human Mutation, 2012, 33, 1123-1132.	1.1	35

#	Article	IF	CITATIONS
451	Genome-Wide Association Study Identifies a Possible Susceptibility Locus for Endometrial Cancer. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 980-987.	1.1	32
452	Abstract LB-447: Functional validation of a genetic locus in the VEGFR-1 tyrosine kinase (TK) domain as a predictive marker for bevacizumab. , 2012, , .		1
453	Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS ONE, 2012, 7, e42380.	1.1	51
454	Abstract LB-331: Polymorphisms in inflammation pathway genes and endometrial cancer. , 2012, , .		0
455	Abstract OT2-2-02: Prospective multicentre study evaluating the effect of impaired tamoxifen metabolization on efficacy in breast cancer patients receiving tamoxifen in the neo-adjuvant or metastatic setting - The CYPTAM-BRUT 2 trial , 2012, , .		Ο
456	Abstract P3-05-03: Characterization of PIK3CA mutations in lobular breast cancer. , 2012, , .		0
457	Abstract P6-07-14: Mutational and transcriptomic characterization of breast cancer (BC) arising in young patients (pts) and during pregnancy and their associations with long-term outcome. , 2012, , .		Ο
458	Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor–Positive, Lower Grade Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2222-2231.	1.1	27
459	Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. Journal of the National Cancer Institute, 2011, 103, 250-263.	3.0	596
460	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2011, 20, 3289-3303.	1.4	152
461	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor–negative breast cancer. Nature Genetics, 2011, 43, 1210-1214.	9.4	279
462	7115 POSTER DISCUSSION ABCB-1 and VEGFR-3 Single Nucleotide Polymorphisms (SNPs) and Outcome on Sunitinib (SUN) Treatment in Metastatic Clear Cell Renal Cell Carcinoma (RCC). European Journal of Cancer, 2011, 47, S509.	1.3	1
463	1412 POSTER Genetic Markers in Relation to Bevacizumab-induced Hypertension. European Journal of Cancer, 2011, 47, S172-S173.	1.3	1
464	1414 POSTER Single Nucleotide Polymorphism Analysis and Outcome in Advanced-stage Cancer Patients Treated With Bevacizumab. European Journal of Cancer, 2011, 47, S173.	1.3	9
465	Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet, The, 2011, 377, 2103-2114.	6.3	876
466	Vitamin D Binding Protein Phenotypes Have An Impact On Vitamin D Substitution In COPD. , 2011, , .		0
467	Functional Polymorphisms in the TERT Promoter Are Associated with Risk of Serous Epithelial Ovarian and Breast Cancers. PLoS ONE, 2011, 6, e24987.	1.1	48
468	Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nature Chemical Biology, 2011, 7, 285-295.	3.9	450

#	Article	IF	CITATIONS
469	Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nature Genetics, 2011, 43, 333-338.	9.4	1,685
470	Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nature Genetics, 2011, 43, 451-454.	9.4	141
471	Comprehensive fine mapping of chr12q12-14 and follow-up replication identify activin receptor 1B (ACVR1B) as a muscle strength gene. European Journal of Human Genetics, 2011, 19, 208-215.	1.4	40
472	Large-Scale Gene-Centric Analysis Identifies Novel Variants for Coronary Artery Disease. PLoS Genetics, 2011, 7, e1002260.	1.5	203
473	Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAs. Breast Cancer Research and Treatment, 2011, 129, 767-776.	1.1	45
474	Identification and prioritization of NUAK1 and PPP1CC as positional candidate loci for skeletal muscle strength phenotypes. Physiological Genomics, 2011, 43, 981-992.	1.0	9
475	Neuronal FLT1 receptor and its selective ligand VEGFâ€B protect against retrograde degeneration of sensory neurons. FASEB Journal, 2011, 25, 1461-1473.	0.2	45
476	Platinum Sensitivity–Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients. Clinical Cancer Research, 2011, 17, 5490-5500.	3.2	57
477	Assessment of Hepatocyte Growth Factor in Ovarian Cancer Mortality. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1638-1648.	1.1	31
478	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortiumâ€. Human Molecular Genetics, 2011, 20, 4693-4706.	1.4	71
479	The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. Clinical Cancer Research, 2011, 17, 3742-3750.	3.2	47
480	Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?. Journal of Clinical Oncology, 2011, 29, 1-4.	0.8	148
481	Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer. Cancer Research, 2011, 71, 6240-6249.	0.4	109
482	The TERT-CLPTM1L locus for lung cancer predisposes to bronchial obstruction and emphysema. European Respiratory Journal, 2011, 38, 924-931.	3.1	25
483	The P450 oxidoreductase <i>*28</i> SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics, 2011, 12, 1281-1291.	0.6	116
484	Breast cancer susceptibility polymorphisms and endometrial cancer risk: a Collaborative Endometrial Cancer Study. Carcinogenesis, 2011, 32, 1862-1866.	1.3	5
485	Progesterone receptor gene variants and risk of endometrial cancer. Carcinogenesis, 2011, 32, 331-335.	1.3	22
486	Opportunities and Challenges in the Genetics of COPD 2010: An International COPD Genetics Conference Report. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2011, 8, 121-135.	0.7	43

#	Article	IF	CITATIONS
487	Polymorphisms in Stromal Genes and Susceptibility to Serous Epithelial Ovarian Cancer: A Report from the Ovarian Cancer Association Consortium. PLoS ONE, 2011, 6, e19642.	1.1	5
488	CYPTAM-BRUT 2: A prospective multicenter observational study in the neoadjuvant and metastatic setting investigating tamoxifen response between women with a favorable versus unfavorable endoxifen profile Journal of Clinical Oncology, 2011, 29, TPS140-TPS140.	0.8	0
489	P2-06-02: FOXO3a Genotype Predicts Age of Breast Cancer Onset and Correlates with Lymph Node Involvement , 2011, , .		0
490	P5-05-01: Vitamin D Status in Newly Diagnosed Breast Cancer Patients Inversely Correlates with Tumor Size and Moderately Correlates with Outcome , 2011, , .		0
491	P1-08-20: Parity Interferes with the Effect of Age at Diagnosis on the Frequency Breast Cancers Are Triple-Negative , 2011, , .		Ο
492	Microglial Upregulation of Progranulin as a Marker of Motor Neuron Degeneration. Journal of Neuropathology and Experimental Neurology, 2010, 69, 1191-1200.	0.9	64
493	A variant at chromosome 9p21 is associated with recurrent myocardial infarction and cardiac death after acute coronary syndrome: The GRACE Genetics Study. European Heart Journal, 2010, 31, 1132-1141.	1.0	50
494	Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. Breast Cancer Research, 2010, 12, R110.	2.2	82
495	Downregulation of genes with a function in axon outgrowth and synapse formation in motor neurones of the VEGFI (I´ mouse model of amyotrophic lateral sclerosis. BMC Genomics, 2010, 11, 203.	1.2	38
496	The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. Gynecologic Oncology, 2010, 117, 358-365.	0.6	53
497	Pharmaco-epigenomics: discovering therapeutic approaches and biomarkers for cancer therapy. Heredity, 2010, 105, 152-160.	1.2	25
498	Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature Genetics, 2010, 42, 880-884.	9.4	235
499	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nature Genetics, 2010, 42, 874-879.	9.4	321
500	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population. Nature Genetics, 2010, 42, 885-892.	9.4	309
501	Genetic evidence for a role of IL33 in nasal polyposis. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 616-622.	2.7	50
502	The 15q24/25 Susceptibility Variant for Lung Cancer and Chronic Obstructive Pulmonary Disease Is Associated with Emphysema. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 486-493.	2.5	92
503	Matrix-Binding Vascular Endothelial Growth Factor (VEGF) Isoforms Guide Granule Cell Migration in the Cerebellum via VEGF Receptor Flk1. Journal of Neuroscience, 2010, 30, 15052-15066.	1.7	75
504	No Association between <i>FTO</i> or <i>HHEX</i> and Endometrial Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2106-2109.	1.1	24

#	Article	IF	CITATIONS
505	Impaired Autonomic Regulation of Resistance Arteries in Mice With Low Vascular Endothelial Growth Factor or Upon Vascular Endothelial Growth Factor Trap Delivery. Circulation, 2010, 122, 273-281.	1.6	37
506	Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene. Thorax, 2010, 65, 215-220.	2.7	379
507	The Association of the 4q25 Susceptibility Variant for Atrial Fibrillation With Stroke Is Limited to Stroke of Cardioembolic Etiology. Stroke, 2010, 41, 1850-1857.	1.0	76
508	Genomic Copy Number Determines Functional Expression of β-Defensin 2 in Airway Epithelial Cells and Associates with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 163-169.	2.5	37
509	A new approach to imprinting mutation detection in GNAS by Sequenom EpiTYPER system. Clinica Chimica Acta, 2010, 411, 2033-2039.	0.5	24
510	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncology, The, 2010, 11, 753-762.	5.1	1,915
511	Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE) Tj ETQq1 1	0.784314 1.0	rgBT/Overloo
512	PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer. Clinical Cancer Research, 2009, 15, 3184-3188.	3.2	296
513	Rare but Relevant Kidney Disorders. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1701-1704.	2.2	0
514	Thrombomodulin Mutations in Atypical Hemolytic–Uremic Syndrome. New England Journal of Medicine, 2009, 361, 345-357.	13.9	495
515	Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the -2578AA genotype. Journal of Medical Genetics, 2009, 46, 840-846.	1.5	70
516	0183 Progranulin (PC-derived growth factor) levels in serum do not predict response to neoadjuvant capecitabine (X), docetaxel (T) and trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC). Breast, 2009, 18, S64-S65.	0.9	0
517	Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users. Breast Cancer Research and Treatment, 2009, 118, 531-538.	1.1	14
518	Role and Therapeutic Potential of VEGF in the Nervous System. Physiological Reviews, 2009, 89, 607-648.	13.1	385
519	16LBA VEGFR-1 polymorphisms as potential predictors of clinical outcome in bevacizumab-treated patients with metastatic pancreatic cancer. European Journal of Cancer, Supplement, 2009, 7, 10.	2.2	10
520	Analysis of <i>FGGY</i> as a risk factor for sporadic amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 441-447.	2.3	15
521	The role of KRAS, BRAF, NRAS, and PIK3CA mutations as markers of resistance to cetuximab in chemorefractory metastatic colorectal cancer. Journal of Clinical Oncology, 2009, 27, 4020-4020.	0.8	28
522	Neurovascular signalling defects in neurodegeneration. Nature Reviews Neuroscience, 2008, 9, 169-181.	4.9	316

#	Article	IF	CITATIONS
523	Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nature Genetics, 2008, 40, 170-180.	9.4	433
524	Genetics, epigenetics and pharmacoâ€(epi)genomics in angiogenesis. Journal of Cellular and Molecular Medicine, 2008, 12, 2533-2551.	1.6	51
525	Novel Role for Vascular Endothelial Growth Factor (VEGF) Receptor-1 and Its Ligand VEGF-B in Motor Neuron Degeneration. Journal of Neuroscience, 2008, 28, 10451-10459.	1.7	119
526	Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. Journal of Cell Biology, 2008, 181, 37-41.	2.3	376
527	Role of VEGF-D and VEGFR-3 in developmental lymphangiogenesis, a chemicogenetic study in Xenopus tadpoles. Blood, 2008, 112, 1740-1749.	0.6	47
528	Role of Gas6 in erythropoiesis and anemia in mice. Journal of Clinical Investigation, 2008, 118, 583-96.	3.9	84
529	Heterogeneity in motoneuron disease. Trends in Neurosciences, 2007, 30, 536-544.	4.2	17
530	Vascular endothelial growth factor counteracts the loss of phosphoâ€Akt preceding motor neurone degeneration in amyotrophic lateral sclerosis. Neuropathology and Applied Neurobiology, 2007, 33, 499-509.	1.8	53
531	VEGF at the neurovascular interface: Therapeutic implications for motor neuron disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 1109-1121.	1.8	91
532	Another angiogenic gene linked to amyotrophic lateral sclerosis. Trends in Molecular Medicine, 2006, 12, 345-347.	3.5	30
533	Gene prioritization through genomic data fusion. Nature Biotechnology, 2006, 24, 537-544.	9.4	787
534	VEGF, an Angiogenic Factor with Neurotrophic Activity, Useful for Treatment of ALS?. , 2006, , 239-252.		0
535	A genetic Xenopus laevis tadpole model to study lymphangiogenesis. Nature Medicine, 2005, 11, 998-1004.	15.2	212
536	Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nature Neuroscience, 2005, 8, 85-92.	7.1	464
537	Low expression VEGF haplotype increases the risk for tetralogy of Fallot: a family based association study. Journal of Medical Genetics, 2005, 42, 519-522.	1.5	59
538	Genetics in Zebrafish, Mice, and Humans to Dissect Congenital Heart Disease: Insights in the Role of VEGF. Current Topics in Developmental Biology, 2004, 62, 189-224.	1.0	34
539	Genetic spotlight on a blood defect. Nature, 2004, 427, 592-593.	13.7	9
540	VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. BioEssays, 2004, 26, 943-954.	1.2	476

#	Article	IF	CITATIONS
541	Sculpting Heart Valves with NFATc and VEGF. Cell, 2004, 118, 532-534.	13.5	27
542	VEGF: necessary to prevent motoneuron degeneration, sufficient to treat ALS?. Trends in Molecular Medicine, 2004, 10, 275-282.	3.5	45
543	Endovascular Treatment of the Descending Thoracic Aorta. European Journal of Vascular and Endovascular Surgery, 2003, 26, 437-444.	0.8	80
544	VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nature Genetics, 2003, 34, 383-394.	9.4	794
545	VEGF: A modifier of the del22q11 (DiGeorge) syndrome?. Nature Medicine, 2003, 9, 173-182.	15.2	288
546	Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nature Medicine, 2003, 9, 936-943.	15.2	699
547	Determinants of 25-hydroxyvitamin D Status in a Cutaneous Melanoma Population. Acta Dermato-Venereologica, 0, 102, adv00692.	0.6	2
548	Decoding the activated stem cell phenotype of the neonatally maturing pituitary. ELife, 0, 11, .	2.8	10